Elmar Jaeckel News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Elmar jaeckel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Elmar Jaeckel Today - Breaking & Trending Today
11 February 2021 · Further commitment of £25.3 million in a £61.0 million expanded Series A; taking Syncona s total commitment to Quell to £59.3 million · First company globally targeting liver transplantation with engineered T regulatory cell therapy; set for clinical entry in the first half of 2022
· Research programmes initiated in Type 1 Diabetes ( T1D ) and Amyotrophic Lateral Sclerosis ( ALS ) Syncona Ltd ( Syncona ) announces a £25.3 million new commitment in a £61.0 million expanded Series A financing for Quell Therapeutics ( Quell ). This is the largest amount of funding to date for any stand-alone engineered T regulatory cell (Treg) company and this new commitment takes Syncona s total commitment to this business to £59.3 million. Syncona has invested £35.1 million of its total commitment and values its investment at that amount (equivalent to cost). Syncona will have a ....
Quell Therapeutics Expands Series A Financing to $84 Million Search jobs Quell Therapeutics Expands Series A Financing to $84 Million – Largest Series A in the Treg field –
London, UK – February 11 2021 – Quell Therapeutics Ltd (“Quell”), a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced the closing of an extended Series A financing led by their existing investors Syncona Ltd (“Syncona”), who have committed an additional $34.7 million and UCL Technology Fund (“UCLTF”) who have committed an additional $1 million; bringing the total Series A financing to circa $84 million.
Quell is funded to progress its program in liver transplantation to clinical proof of concept, whilst expanding its portfolio into autoimmune and neuroinflammatory diseases. Additionally, the funding will allow the Company to further develop scalable manufacturing processes and expand its senior le ....